Expression of fatty acid synthase in nonalcoholic fatty liver disease.
about
Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver diseaseGlial cell line-derived neurotrophic factor protects against high-fat diet-induced hepatic steatosis by suppressing hepatic PPAR-γ expressionAMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant miceProanthocyanidins modulate microRNA expression in human HepG2 cellsDiet-induced adipose tissue expansion is mitigated in mice with a targeted inactivation of mesoderm specific transcript (Mest).Molecular pathways in non-alcoholic fatty liver disease.Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liverExpression and function of methylthioadenosine phosphorylase in chronic liver disease.Fatty acid synthase-positive hepatocytes and subsequent steatosis in rat livers by irinotecan.Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.Selective inhibition of liver X receptor α-mediated lipogenesis in primary hepatocytes by licochalcone ACharacterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosisMimp/Mtch2, an Obesity Susceptibility Gene, Induces Alteration of Fatty Acid Metabolism in Transgenic Mice.The Fatty Acid Synthase Inhibitor Platensimycin Improves Insulin Resistance without Inducing Liver Steatosis in Mice and MonkeysA20 Attenuates FFAs-induced Lipid Accumulation in Nonalcoholic Steatohepatitis.Increased serum levels of lipogenic enzymes in patients with severe liver steatosis.Effect of chronic psychosocial stress on nonalcoholic steatohepatitis in miceIdentification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro.Fat accumulation in the liver of obese rats is alleviated by soy protein isolate through β-catenin signaling.Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis.Network analyses identify liver-specific targets for treating liver diseases.Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice.Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation.Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes.Hepatic Peroxisome Proliferator-Activated Receptor Gamma Signaling Contributes to Alcohol-Induced Hepatic Steatosis and Inflammation in Mice.Tetrabromobisphenol A activates the hepatic interferon pathway in rats.circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.Chinese olive extract ameliorates hepatic lipid accumulation in vitro and in vivo by regulating lipid metabolism.
P2860
Q28072381-1982C153-C389-4104-AB90-922B1673D6B1Q28354027-9C28FF38-2051-437F-B7E7-B81061D54339Q28591122-111617F0-01EF-4373-94F2-7B3757F80F0FQ31037878-A44CDEA0-B26E-4E64-9DD1-AAD2ACF41D60Q33825610-81C43FE6-8560-4226-859F-55BE253D0D8CQ33890230-B9C24EC1-A11F-4A29-817C-E93A5E8B2808Q34728811-77039CFA-BBE9-4D7B-83FA-BF1EB952D4E9Q35063777-A514236E-770E-45FC-9496-F0F6EBB24DA5Q35343063-ED0D1030-D831-43E7-B44F-DDE27D24FEE5Q35532289-6A7BC3B1-65A7-4FE0-8385-4C251138A362Q35559490-A8B45F45-2623-4F56-9583-384C9B01D66EQ35972941-7EC8221E-064A-4013-AFFA-42A7FF766202Q36064668-2817D882-40CC-4978-AF98-4F4A40777644Q36151024-E8131C3D-9157-4D37-90C7-3E14863D3F03Q36352736-AB630651-A63B-4BC0-80F1-6005330658DDQ36388329-AE13A59D-2C6A-43EA-98FD-D38D6CDB7AF0Q37054565-80530AA5-12F3-4998-AE11-8D4C06E8E9C6Q38310825-C66590C2-F677-41AB-8E92-349954571CAFQ39178223-38913856-4D93-41B9-AA4C-610E6B04693DQ39657367-13F6611A-0B5F-4F67-B608-5039E7F2603FQ41490008-9F484E10-1CFF-46E5-B400-50B8B8039E68Q41526807-850E627A-C939-43D9-9408-92BCDDAC7A3CQ42051129-43EA5BA4-8DC9-4A4C-9BCD-1F9034CE3216Q42806308-FBD49B14-7E0B-4B07-9F6B-E0DCF9280A8CQ46237033-B09DEB42-9026-4863-A846-904C61F3FE7EQ47143305-C5BB6210-4647-4A72-8392-C73813A3A4F5Q47927359-AC5C744C-D73D-426C-9FF9-149DEDAE4700Q49387786-38647E5B-C46B-40BC-A24D-F941BFA49F5DQ49885231-32DF3ADF-368A-4BB8-9413-6835337E8FD6Q49951009-DE585E74-7758-40F0-9306-B6D466FA18E9
P2860
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@ast
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@en
type
label
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@ast
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@en
prefLabel
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@ast
Expression of fatty acid synthase in nonalcoholic fatty liver disease.
@en
P2093
P2860
P1476
Expression of fatty acid synthase in nonalcoholic fatty liver disease
@en
P2093
Arndt Hartmann
Christoph Dorn
Claus Hellerbrand
Erwin Gäbele
Georgi Kirovski
Glen Kristiansen
Kathrin Steib
Marc-Oliver Riener
Michael Saugspier
Thomas S Weiss
P2860
P304
P577
2010-03-25T00:00:00Z